The investment comes as enterprises race to secure a rapidly expanding AI attack surface, from foundation models to the autonomous agents now writing and shipping code on their behalf.

AUSTIN, Texas, Sept. 2, 2026 — HiddenLayer, the leading AI security company that secures agentic, generative, and predictive AI applications, today announced a $100 million Series B funding round led by Delta-v Capital, with participation from Ten Eleven Ventures, Morgan Stanley, M12, Microsoft’s Venture Fund, and Booz Allen Ventures.

The company will use the funding to deepen its enterprise platform, including its Agentic Runtime Security capabilities, and Agent Harness Security, a new solution that extends the Runtime Security module to secure AI coding agents at runtime and protect enterprises adopting autonomous coding agents into their stack.             

“We set out to pioneer trusted, secure use of AI for enterprises, long before most organizations saw the urgency we do today. This funding lets us keep growing the purpose-built team and platform required to meet that moment as agentic AI becomes core to how enterprises operate,” said Chris Sestito, CEO and Co-Founder of HiddenLayer.

The raise follows a standout year: HiddenLayer’s annual recurring revenue grew more than 10x, and the company signed more than 50 new platform customers, including some of the largest names in securities brokerage, banking, insurance, accounting, government, technology, IT services, pharmaceuticals, airlines, and the US defense and intelligence communities. Internationally, new customers included one of the world’s largest pharmaceutical companies, along with several premium automotive brands and food and beverage providers. HiddenLayer also supports a leading frontier model provider in securing more than 700 million weekly users.

This growth is underpinned by a world-class research team that has directly influenced how leading organizations protect their AI systems. HiddenLayer’s researchers hold 39 granted patents and 65 pending patents spanning adversarial detection, model protection, and AI threat analysis. The team developed the first comprehensive Adversarial Prompt Engineering (APE) Taxonomy and continues to research emerging threats across generative, predictive, and agentic AI, identifying dozens of vulnerabilities across the AI ecosystem, from foundation models to the tools and infrastructure that support them. HiddenLayer’s researchers also contribute to the broader AI security community through work with organizations and initiatives including CISA/JCDC, MITRE, NIST, OWASP, and OpenSSF, improving red teaming methodologies and informing global discussions on AI governance and safety.

“Traditional security tools were built for code and infrastructure, not for models that can be poisoned, hijacked, or manipulated through their own inputs,” said Dan Williams, Partner at Delta-v Capital. “HiddenLayer built a platform from the ground up to secure AI across its full lifecycle, from the model at its core to the agentic systems being layered on top and whatever architecture comes next. We’ve watched this team turn deep adversarial-AI research into a product CISOs actually rely on, and we’re proud to partner with them.”

The funding allows HiddenLayer to focus on the three fronts where enterprises are most exposed: Agentic Runtime Security, giving organizations visibility into how their AI agents behave in production, flagging and stopping manipulation, tool misuse, and unauthorized actions as they happen, and securing Agentic Harnesses and Autonomous Coding Agents that write, review, and ship code with much less human oversight than traditional development tools. As AI cannot be made trustworthy through design-time principles alone, there is no trustworthy AI without end-to-end AI-native security. Trust has to be continuously tested and proven at runtime. These capabilities are designed to give enterprises the confidence to trust their AI, with 96% of organizations already considering AI critical to their core operations, but nearly a third unable to say with certainty whether they’ve experienced an AI-related breach, according to HiddenLayer’s 2026 AI Threat Landscape Report.

“Enterprises don’t shift budgets at this pace unless a problem is urgent. HiddenLayer’s growth over the past year across defense, financial services, and some of the most sensitive AI deployments in the world demonstrates that security teams have concluded that AI needs its own category of protection,” said Mark Hatfield, Co-Founder and Partner at Ten Eleven Ventures. “We expect that conviction to continue to grow as autonomous systems become more and more integral to the enterprise.”

“HiddenLayer was early to recognize that enterprise security is critical to the safe deployment of AI, and its buildout of an end-to-end platform to enable compliant AI adoption is an important contribution to addressing this market need,” said Zheng Wang, Head of Strategic Investments at Morgan Stanley. “We are delighted to be investing in HiddenLayer to foster its next phase of growth and innovation.”

HiddenLayer is also strengthening its leadership team, recently naming Mike Gesnaldo as Chief Revenue Officer. More hires are on the way as the company deepens its channel relationships, keeps pace with enterprise customer demand, and pushes further into international markets, beginning with Europe and the wider EMEA region.

About HiddenLayer
HiddenLayer secures agentic, generative, and predictive AI applications across the entire AI lifecycle, from discovery and AI supply chain security to attack simulation and runtime protection. Backed by patented technology and industry-leading adversarial AI research, our platform is purpose-built to defend AI systems against evolving threats. HiddenLayer protects intellectual property, helps ensure regulatory compliance, and enables organizations to safely adopt and scale AI with confidence.

About Delta-v Capital
Delta-v Capital (“Delta-v”) partners with visionary leaders of technology companies to accelerate their next phase of growth. Delta-v is a sector-focused investor with expertise in infrastructure software, cloud services, vertical software, and digital infrastructure. The firm provides flexible growth capital to support organic growth, strategic acquisitions, and shareholder liquidity, partnering with management teams and existing investors as companies scale. Delta-v currently manages over $1.6B in assets on behalf of institutional and individual investors. For more information, please visit www.deltavcapital.com or follow Delta-v Capital on LinkedIn.

Contact
SutherlandGold for HiddenLayer
[email protected] 

SOURCE HiddenLayer

HyImpulse’s €350M+ order book shows that demand for sovereign, responsive launch is already translating into significant commercial scale. 

WASHINGTON, Sept. 2, 2026 — OMVP today announced that it has co-led a financing of more than €50 million in HyImpulse Technologies GmbH, backing the company as it scales sovereign European launch capabilities. 

HyImpulse is a German company developing suborbital and orbital launch platforms using proprietary hybrid propulsion technology and has already built an order book of more than €350 million. 

“HyImpulse bridges the gap between strategic necessity and commercial demand” said Sean Bielat, Managing Partner of OMVP. “Europe needs resilient, independent access to space, and HyImpulse is building a business around that need.” 

The new capital will support the company’s second SR75 launch, the maiden flight of its SL1 orbital vehicle, expanded production and growth across commercial and defense markets. 

The HyImpulse raise demonstrates OMVP’s unique sourcing advantage. OMVP was the only U.S. participant selected for the round. 

About OMVP 

OMVP is a venture capital firm investing in European defense, dual-use and strategically important technologies.

SOURCE OMVP

Existing investors Greenoaks and Valor Equity Partners co-led the round, with participation from CEO Peter Rahal, ICONIQ, and Imaginary Ventures.

NEW YORK, Sept. 2, 2026 — Medici Brands, the parent company of David Protein and newly launched confectionery brand HallPass, today announced a $250 million Series B financing. The round was co-led by Greenoaks and Valor Equity Partners, with participation from Peter Rahal, ICONIQ, and Imaginary Ventures. Both Valor and Greenoaks previously invested in David’s $75 million Series A in 2025.

In September 2024, David launched direct-to-consumer with a single product: its flagship protein bar, offering 28 grams of protein, 150 calories, and 0g of sugar. In just two years, the brand has expanded from protein bars into frozen dessert and ready-to-drink shakes, and is now sold in more than 35,000 retail locations, including Walmart, Target, and Costco. That growth has put the company on track to surpass $300 million in revenue in 2026, making it the fastest food company to reach that milestone. 

Medici has since expanded its portfolio beyond David with HallPass, a new confectionery brand that launched nationwide at Walmart in August 2026. Across its products, HallPass aims to deliver the taste and experience of classic candy at a fraction of the calories and sugar, without the premium price typically associated with better-for-you products. Later this year, the company plans to launch its third consumer brand, Rowdy.

“We are not interested in telling people to stop eating the foods they love,” said Peter Rahal, CEO of Medici Brands. “We want to improve public health by making those foods smarter: lower calories, less sugar, no compromise on taste or experience. If we can do that across categories, better nutrition becomes easier by default.”

The new capital will be used to accelerate Medici’s next phase of growth, including expanding HallPass’ retail presence and product portfolio, extending David into new formats and categories, advancing product innovation, and building the infrastructure required to support launching and scaling new brands such as Rowdy.

“Two years ago, David Protein showed customers they no longer had to choose between great macros and great taste, and it became one of the fastest-growing CPG brands in America,” said Neil Shah, Partner at Greenoaks. “But that was never the whole ambition. Now, Medici is bringing that approach to the rest of the store, building a house of brands that delivers the taste consumers adore, without making the compromises they have grown to accept. We believe Medici is building the first technology-enabled platform in food, and we are proud to deepen our partnership with Peter and the Medici team.”

“We have tremendous confidence in Peter’s leadership and the business he is building at Medici,” said Jon Shulkin of Valor Equity Partners. “Medici combines exceptional consumer products with differentiated technology, creating a foundation we believe can support multiple category-defining brands. We’re excited to deepen our partnership with the team as they continue to build the company.”

About Medici Brands
Medici Brands creates progress by rethinking the products of the past. Its portfolio includes David Protein, a high-protein food brand, and HallPass, a confectionery brand that delivers sweets that taste like the classics at a fraction of the calories. Medici also owns Epogee, the company behind EPG, a plant-based fat substitute that delivers the taste and texture of traditional fat at a fraction of the calories.

About Greenoaks
Greenoaks makes concentrated, long-term investments in enduring companies around the world, including Stripe, Canva, Discord, Robinhood, and Toast. The firm invests behind exceptional founders at all stages of their journeys, building partnerships that last for decades.

About Valor Equity Partners 
Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development. For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale. Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries. For more information on Valor Equity Partners, please visit www.valorep.com.

SOURCE Medici Brands, Inc.

RIYADH, Saudi Arabia, Sept. 2, 2026 — COFE Tech (formerly COFE APP), the leading operator of agentic AI enterprises and provider of intelligent procurement and AI-powered commerce infrastructure to more than 1,000 businesses across the Gulf, announced yesterday at LEAP 2026 in Riyadh the close of a pre-IPO funding round valuing the company at $178 million. The round was co-led by Wa’ed Ventures, the venture capital arm of Aramco, and Aditum Investment Management, regional fund partner to global asset managers including BlackRock, alongside Masarrah Investment Company and Alyasra Foods. The investment puts COFE Tech, dubbed the ‘Salesforce of MENA,’ on course for a targeted IPO on the Saudi Exchange by 2029.

“Too many companies in our region still run procurement, sales and inventory on systems that do not talk to one another,” said Ali Al-Ebrahim, Founder and CEO of COFE Tech. “COFE Tech brings those operations into a single intelligent enterprise platform, where AI agents watch the business, anticipate what it needs and act on its behalf. Since launching out of Kuwait in 2018, we have scaled across Saudi Arabia and the UAE — a working example of what the Gulf’s innovation-driven economic visions, from Saudi Vision 2030 to Kuwait Vision 2035, and the region’s fast-growing AI ecosystem make possible for ambitious technology companies.”

The pre-IPO round backs COFE Tech’s transformation from a consumer marketplace into an enterprise AI and B2B SaaS platform built on two engines. Agentic Procurement is a unified digital procurement solution where autonomous AI agents forecast demand, automate purchase orders and approvals, track inventory in real time, and manage e-invoicing, supply chain logistics, vendor management and embedded finance — including COFE Pay, a buy-now-pay-later (BNPL) fintech service. Agentic Commerce lets brands run AI-powered e-commerce, digital payments, digital wallets, loyalty programs and customer engagement on one platform, featuring One AI’s ‘Talk to Your Data’ generative AI capability. Both run alongside the company’s direct-to-consumer coffee marketplace app.

Driving digital transformation across the GCC, COFE Tech serves more than 1,000 enterprise clients across 3,000 outlets in Saudi Arabia, Kuwait and the United Arab Emirates, spanning food and beverage, hospitality, aviation, healthcare, education and retail. Clients include Emirates, Etihad Airways, Kuwait Airways, Al-Futtaim Group, Kuwait Finance House, the Central Bank of Kuwait, stc, Aramco and Alibaba Cloud.

SOURCE COFE Tech

MIAMI, Sept. 2, 2026 — H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $75 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Outcomes One (“Outcomes” or the “Company”), a leading provider of clinical network services and pharmacy technology.

Headquartered in Orlando, Florida, Outcomes provides clinical network services and pharmacy technology solutions to pharmacies, health plans, pharmaceutical manufacturers, and data partners. Through its leading national network, which encompasses approximately 85% of U.S. pharmacies, the Company meaningfully improves patient health by enabling pharmacist-delivered clinical interventions and medication-based care. In 2025, the Company facilitated more than 10 million clinical interventions across 130 million covered lives. The Company additionally provides an integrated technology suite, including pharmacy management software and workflow automation solutions, to pharmacies nationwide, supporting critical daily operations such as prescription processing, dispensing, billing, and inventory management. Outcomes’ solutions span national and regional pharmacy chains, health systems, specialty and long-term care providers, and independent community pharmacies.

Jude Dieterman, Chief Executive Officer of Outcomes, noted, “Outcomes was built around the belief that pharmacists play a critical role in improving patient health. Our partnership with H.I.G. will provide additional resources and expertise to continue investing in our unique pharmacist-led clinical network, our leading technology platforms such as Rx30, Computer-Rx, and Outcomes Premium, and to deliver even greater value to pharmacies, health plans, pharmaceutical manufacturers, and patients.”

“Outcomes has built a unique technology platform that enables critical health services that are proven to improve patient outcomes,” commented Arjun Mohan, Managing Director at H.I.G. “We are excited to further that cause by partnering with the Outcomes team to support their commitment to deliver quality technology, services, and innovation to customers while elevating the role of pharmacies in the healthcare system.”

H.I.G. was advised by William Blair & Co. LLC and Kirkland & Ellis LLP. Outcomes was advised by TripleTree LLC and Simpson Thacher & Bartlett LLP.

About Outcomes

Outcomes is a leading provider of clinical network services and pharmacy technology that puts the pharmacy at the center of healthcare. Through its national network and integrated technology suite, the Company facilitates clinical interventions, improves medication adherence and patient health, streamlines pharmacy operations, and creates new economic opportunities for pharmacy partners. Outcomes’ solutions include its clinical platform, pharmacy management software, patient engagement and automation tools, and data and analytics. For more information, please visit outcomes.com.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $75 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach: 

• H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
• H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets.
• H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
• H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and its affiliates.

Contact:

Arjun Mohan
Managing Director
[email protected]

Christopher Kozak
Principal
[email protected]

H.I.G. Capital
1450 Brickell Avenue
31st Floor
Miami, FL 33131
P: 305.379.2322
hig.com

SOURCE H.I.G. Capital

AUSTIN, Texas, Sept. 2, 2026 — Critical Materials Group (CMG), a privately owned U.S.-based manufacturing company modernizing domestic energetics production, today announced it has raised $10.3M in Seed funding led by Overmatch Ventures, with participation from Victory Six Advisors and Fulcrum Ventures. The round will be used to accelerate development and commissioning of CMG’s modular energetics production platform, expand the company’s engineering and operations team, and advance regulatory milestones.

The investment comes as demand for domestic munitions and advanced energetics production reaches a critical inflection point. Decades of consolidation have left U.S. energetics manufacturing concentrated in a small number of facilities with limited surge capacity, creating strategic vulnerabilities that have grown more acute amid sustained global conflict and accelerating allied demand. CMG is developing modular, automation-ready production platforms designed to expand and strengthen the existing industrial base, giving established manufacturers and defense primes the capacity, flexibility, and resilience needed to meet sustained production requirements without disrupting proven operations.

“The U.S. energetics industrial base, from the GOCOs to the prime contractors that depend on them, has been the backbone of American energetics for generations – CMG was built to add capacity to that ecosystem,” said Kevin Capozzoli, CEO and Co-Founder of Critical Materials Group.” This funding accelerates our ability to bring modular, automation-ready production online as a complementary source that gives the industrial base the flexibility and surge capacity it needs to meet a demand signal that isn’t slowing down.”

The Seed funding will also allow CMG to meet current commitments across its contract portfolio and move faster on facility commissioning as demand from U.S. government customers continues to build. The company is simultaneously building out its government relations and regulatory compliance infrastructure to support long-term production partnerships.

“CMG sits at the intersection of geopolitics and deep tech. Energetics, like rare earth minerals, sit upstream of nearly every U.S. kinetic capability, and recent conflicts have exposed the enormous gap between peacetime production and wartime consumption. But Kevin and Travis are ultimately why we led this round. Kevin is an uncommon combination of end-user and exceptional operator. He has seen firsthand what a thin industrial base costs downrange. Travis runs one of the few private labs in the country that can formulate, test, and qualify energetic materials. Together, they are the team to rebuild the arsenal we need to deter, and if necessary defeat, our adversaries,” said Morgan Hitzig, General Partner at Overmatch Ventures.

Founded in 2025, CMG has moved quickly to establish technical credibility and government alignment in a sector defined by long procurement cycles and high barriers to entry. The company’s founding team brings experience from military service, defense contracting, and procurement, positioning itself as a trusted partner capable of filling the arsenal gaps the modern threat environment demands.

About Critical Materials Group (CMG):
Founded in 2025, Critical Materials Group, Inc. (CMG) is a privately held, Texas-based manufacturing company modernizing energetics production facilities critical to national security. CMG delivers modular, automation-ready production platforms and integrated techniques that embed safety into every stage of the manufacturing process, enabling resilient, scalable, and responsible domestic energetics production. Led by industry experts from laboratory and operational backgrounds, CMG is committed to safely and responsibly enabling lethality at scale to support allied defense readiness.

Media Contact:
[email protected]

SOURCE Critical Materials Group

– Typewriter’s site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines –

– Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael Dolsten, MD, PhD, joins Typewriter board as independent director and the Fred Hutch’s Stanley R. Riddell, MD, joins Typewriter Scientific Advisory Board –

CAMBRIDGE, Mass. and TOKYO, Sept. 2, 2026 — Typewriter Therapeutics, Inc., a biotech company developing safe, durable and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases, today emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management with participation from ANRI, Gemseki, and SBI US Gateway Fund. In addition, Typewriter announced the appointments of Matthew Stanton, PhD, as Chief Executive Officer, Leanne Peiser, DPhil, as Chief Scientific Officer, and Mikael Dolsten, MD, PhD, as a member of the company’s board of directors.

Typewriter’s Target-Primed Reverse Transcription (TPRT) technology platform is built on the R2 retrotransposon, a natural gene-insertion system discovered by the company’s academic co-founders. Typewriter’s two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving only the inserted gene at its intended location.

Typewriter’s initial focus will be on two high-value indications with life-changing potential to patients: in vivo CAR T and genetic liver diseases. The company’s first NHP studies are planned for late 2026.

“By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches,” said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics. “This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate.”

Prior to Typewriter, Matthew Stanton was a Venture Partner at Raven, RA Capital’s healthcare incubator. Before Raven, he spent seven years at Generation Bio, first as Chief Technology Officer and for the past five years as Chief Scientific Officer. Prior to Generation, he was Vice President and Head of Chemistry at Moderna Therapeutics, where his team identified proprietary lipid nanoparticles for vaccine development and helped to bring the first mRNA vaccines into clinical development.

Newly appointed CSO Leanne Peiser brings to Typewriter more than 20 years of R&D leadership across biotech and pharma, with deep expertise in immunology, immunotherapy, and cellular therapy, including autologous, allogeneic, and in vivo CAR T for oncology and autoimmune diseases. Most recently, as Executive Director of Translational Research, Cellular Therapy at Bristol Myers Squibb (BMS), she served as a senior scientific lead for their CAR T portfolio across multiple indications.

“The mRNA vaccines proved to the world that RNA delivered by a lipid nanoparticle can become a medicine at global scale. Typewriter takes that breakthrough a decisive step further –using only RNA not to express a transient protein, but to write a durable therapeutic gene into a precise, safe location in the genome, without a virus,” said Mikael Dolsten, MD, PhD, independent board director at Typewriter Therapeutics and former Chief Scientific Officer and President of Worldwide Research & Development at Pfizer. “I am especially excited by what this means for in vivo CAR T. Engineering a patient’s own T cells in vivo with an LNP-delivered RNA medicine could combine simpler administration with durable CAR expression and the ability to re-dose, potentially making cell therapy safer and accessible to far more patients than today’s complex manufacturing allows. It is a privilege to join the board and help bring this platform to patients with cancer, autoimmune, and genetic diseases.”

Typewriter is led by an experienced management team, including:

• Matthew Stanton, PhD, Chief Executive Officer
• Leanne Peiser, DPhil, Chief Scientific Officer
• Jun Zhou, PhD, Founder and Vice President, Discovery and Global Operations
• Ari Friedland, PhD, Vice President, Research
• Mayu Yoshikawa, PhD, President, Typewriter Japan

In addition to Matthew Stanton and Mikael Dolsten, Typewriter’s board of directors includes board chair Ken Horne, Managing Partner, AN Venture Partners and Laura Tadvalkar, PhD, Managing Director at RA Capital.

Typewriter also announced that Stanley R. Riddell, MD, has joined as a member of its Scientific Advisory Board. Dr. Riddell is a member of the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and Professor of Medicine at the University of Washington. He was the principal investigator on the first human trial of adoptively transferred therapeutic T cells, and his laboratory’s CAR T work was licensed to Juno Therapeutics, which he co-founded and which is now part of Bristol Myers Squibb.

About Typewriter Therapeutics

Typewriter Therapeutics is a start-up company that focuses on developing and commercializing RNA-based gene therapies for patients suffering from cancer, autoimmune, and severe genetic disorders. Typewriter’s cutting-edge platform technology enables the targeted insertion of whole therapeutic genes to create safer, durable, and re-dosable medicines. Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. For more information, visit www.typewritertx.com.

SOURCE Typewriter Therapeutics, Inc.

• IBM Ventures has invested in BQP, bringing total funding to $8M and backing BQP’s expansion from engineering design into real-time operational decisions. The investment extends a technical relationship that began in 2023, when BQP joined the IBM Quantum Network.
• Classical solvers leave roughly 85% of a GPU’s floating-point capacity idle. BQP’s flagship platform, BQPhy®, puts that capacity to work, resolving full-fidelity physics inside operational decision windows.
• BQPhy® is in production with aerospace and defense customers, with contracted and committed revenue up 8x since BQP’s 2025 seed round and 3x customer growth.

SYRACUSE, N.Y., Sept. 2, 2026 — BQP, the physics acceleration company, today announced a strategic investment from IBM Ventures, the venture capital arm of IBM. The investment brings BQP’s total funding to $8M and funds BQPhy®’s expansion from engineering design into operational deployment, scaling delivery and go-to-market as BQP expands beyond aerospace and defense. Venn10 Capital and existing investor Monta Vista Capital also participated. Since its 2025 seed round, backed by New York State’s venture arm and other institutional investors, BQP has grown contracted and committed revenue 8x, tripling its customer base and growing platform users 20x.

“An engineer with a deadline doesn’t care where the answer came from. They care that it arrived in time and that the physics is right. The industry spent years treating this as a hardware problem that warranted faster chips, more of them, and eventually a quantum one. But it was always a software problem,” said Abhishek Chopra, Founder and CEO of BQP.

Chopra added: “We spent those years earning our way into engineering workflows, so when the quantum machines are ready, nothing about how those teams work has to change. That’s the path IBM has watched us build since 2023, and this investment says it’s the right one.”

Mission-critical decisions have deadlines, and high-fidelity physics simulations rarely meet them. More hardware has not closed the gap. Classical physics solvers leave roughly 85% of a GPU’s floating-point capacity idle, because the sparse iterative methods underneath simulation are bound by memory access rather than compute. Teams choose between accurate models that return the right answer too late, or fast methods that answer on time by skipping the physics, leaving hidden risk behind over-engineered safety margins.

BQPhy® removes this trade-off between speed and accuracy. Its physics-AI optimization engine resolves the full physics inside the decision window, using the GPU capacity classical solvers leave idle. The platform delivers this through two solvers that share a single SDK, integrated natively into MATLAB as a MathWorks Connections Program partner, with standard APIs for Python, Julia, and other frameworks. This enables engineers to get the answers without leaving the tools they already use. QuantumNOW™ is in production today on customers’ existing CPU and GPU infrastructure, and each deployment maps which problems belong on a QPU – making QuantumMAX™, BQP’s quantum-native solver in development, an on-ramp rather than a bet. It is written for heterogeneous CPU-GPU-QPU execution rather than a single hardware target.

“What stood out with BQP is that users don’t have to change how they work to get quantum-accelerated results. Their proven track record of developing software that helps enterprises build a practical path toward hybrid quantum-classical computing is what gives IBM Ventures confidence in making this investment,” said Emily Fontaine, Global Head of IBM Ventures.

In aerospace and defense, BQP’s furthest-along work is in space. Under an SBIR with the U.S. Space Force and SpaceWERX, extending earlier work with the SDA TAP Lab, BQPhy®’s physics AI propagates a catalog of more than 3,000 space objects in under a second, roughly 250x faster than the open-source Orekit solver by compressing the model using proprietary algorithms.BQP also holds a CRADA with the Air Force Research Laboratory’s Aerospace Systems Directorate and has demonstrated BQPhy® on radio-frequency signal problems for the tactical edge with NavalX. With Modovolo, BQP built a system-level propulsion optimization for UAV mission profiles, expanding from three design variables to more than twelve and tuning propeller and motor as a single unit; integration took roughly one week through the API.

In energy, BQP is applying the same platform to commercial systems, with EV battery thermal management work funded by India’s Ministry of Heavy Industries and the Indian School of Business.

The same engine that predicts where a satellite is heading also predicts how heat moves through a battery pack or a data center rack: different industries with the same high-dimensional physics that has to resolve before the decision window closes.

QuantumNOW™ is in production; QuantumMAX™ is proving out. In work presented at USNC/TAM 2026, BQP ran QuantumMAX™ on quantum hardware for uncertainty quantification in computational fluid dynamics, reaching the same accuracy as classical Monte Carlo with fewer samples on a benchmark-scale problem. BQP’s research is published in IEEE, AIAA, and APL Quantum, with best paper awards at AeroCon 2026 and the IEEE Space, Aerospace and Defence Conference (SPACE 2026).

Media Contact
Ludington Media on behalf of BQP
[email protected]
New York, NY • (551) 795-5950

About BQP

BQP (formerly BosonQ Psi) is a physics acceleration company applying quantum algorithms to mission-critical operational decisions. Its unified Quantum-HPC platform, BQPhy®, pairs physics AI surrogates with an optimization solver, delivering results on today’s CPU and GPU infrastructure through QuantumNOW™ with quantum-native acceleration in development through QuantumMAX™ – both on a single SDK. Headquartered in Syracuse, New York, with offices in the UK and India. Learn more at https://www.bqpsim.com

SOURCE BQP

Partnering with Investors and Validators for Social Good

PIERRE, S.D., Sept. 2, 2026 — Aegis Trust, a SEC qualified custodian for digital assets, today announced the development of the world’s first tokenized money market fund that focuses on social impact. Leveraging the blockchain eliminates delays, reduces inefficiencies, and restores trust in global aid systems. Aegis Trust is working with global investors and partners to demonstrate how investment returns and tokenized capital can help fund disaster response and humanitarian relief.

Through a partnership with regulated asset manager, the Tokenization Foundation Money Market Fund is designed to optimize cash management while generating measurable global impact through tokenized aid. Aegis Trust pledges to donate 10% of gross revenue received from this Money Market Fund to humanitarian aid and disaster relief, and benefits investors, aid workers and council members with TF Tokenized Coins.  Investors are also allocated 10% TF Coins up to the first US$10B AUM. Nonprofit organization including aid workers can receive 10% TF Coins from AI-enabled activations and as they accrue TF Coins. As Super Validators, with governing rights to the infrastructure and information rights of the rail including reporting, monitoring, 10% TF Coin are allocated to 10 Council Members.

“The future of financial services is going digital and as the need for blockchain and digital asset financial solutions grows, Aegis Trust is working with global council members to build Tokenization Foundation on crisis capital infrastructure where the blockchain enables instant, traceable, and secure transfers for humanitarian aid,” said Serra Wei, Cofounder of Aegis Trust and the Tokenization Foundation. “The Tokenization Foundation looks to relieve aid trapped in slow grant cycles, burdened by administrative overhead, and limited by opaque reporting systems to deliver funding instantly, transparently, and at scale.”

In addition to Aegis Trust, the Digital Chamber has agreed to become a founding council member. “As the world’s oldest and largest digital assets trade association, we support Aegis Trust’s efforts and are excited to see how the Tokenization Foundation begins to give back and grow broader investment education and social good,” said Anastasia Dellacio, Executive Director of The Digital Chamber’s State Network. “This initiative supports our mission to a fair and inclusive financial ecosystem where everyone has the opportunity to participate.”

Aegis Trust is adding banking expert Steve Andrews as a member of the Board of Director at Aegis Trust to support governance and risk management with current board members Lynne Marlor, Dave Timpe and Todd Bernard. Steve’s long career involved the operational aspects of running five banks as the President and CEO.

About Aegis Trust:

Aegis Trust (https://www.aegiscustody.com), a SEC qualified custodian for blockchain transactions, provides high-quality, secure, institutional-grade, proprietary, integrated custody solutions. Aegis Trust is a blockchain company with offices in the US and utilizes its South Dakota Trust Charter to hold all digital assets in segregated and transparent custody accounts. With an experienced executive team and global partners across traditional and digital financial services, Aegis Trust is building a tokenized ecosystem with impact.

About The Digital Chamber:

The Digital Chamber is a non-profit organization committed to promoting global blockchain adoption. We envision a fair and inclusive digital and financial ecosystem where everyone has the opportunity to participate. Access to digital assets is not merely a technological advancement but a fundamental human right, crucial for economic and social empowerment. Through targeted education, advocacy, and strategic collaborations with government and industry stakeholders, we drive innovation and shape policies that create a favorable environment for the blockchain technology ecosystem.

The Digital Chamber’s umbrella includes: CryptoUK, Digital Power Network (DPN), TDC’s Digital State Network, and Treasury Council.

Media Contact:

Jan Jahosky

[email protected] 

407.331.4699

SOURCE The Tokenization Foundation